*FDA approval decision of Zytiga in Pre-Chemo space on/by Dec 20, 2012. If rejected, lookout!
*Q4/2012 earnings call and the CHMP opinion on Provenge by Jan 30, 2013.
*Q1/2013 and the "Day 277 EMEA decision on Provenge" by/on April 30th, 2013.
All within 5 months away... ;o)
But don't expect major stock moves until hedgefunds are ready to cover...not because they have to because of losses, but because they're ready to and have the majority of the 154 million outstanding shares (when they become hedged long). That's when CEO JJ blows through treating 1076 patients per quarter or decides he's ready to do 100million in revenue.
Hmmm, I'm guessing this occurs by the next DNDN national sales meeting or in Q4, 2013....when all the stock/options they & JJ's officers recieved this year, doubles near the year end of next year (Oct,Nov,Dec ;o)